Tirzepatide — references and citing documents

§10References

Every reference the monograph relies on is listed below in order of first citation across the document. Identifiers are reproduced only where the Institute holds them; where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed one.

This monograph cites 18 sources^{[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18]}.

Table 9. Bibliographic records for the sources cited by this monograph. Each links to its record page, which lists every Institute document citing it.

§11Related Institute documents

Table 10. Institute documents that draw on, or are drawn on by, this monograph.

Numbered reference list

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine 2022;387(3):205–216. doi:10.1056/NEJMoa2206038 · PMID 35658024
2. Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet 2023;402(10402):613–626. doi:10.1016/S0140-6736(23)01200-X · PMID 37385275
3. Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, Halpern B, Zhang S, Chen J, Bunck MC, Ahmad NN, Forrester T. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature Medicine 2023;29(11):2909–2918. doi:10.1038/s41591-023-02597-w · PMID 37840095
4. Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, Ahmad NN, Zhang S, Liao R, Bunck MC, Jouravskaya I, Murphy MA. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 2024;331(1):38–48. doi:10.1001/jama.2023.24945 · PMID 38078870
5. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, Das S, Stefanski A, Sapin H, Rodriguez Flores M. Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine 2025;392(1):45–57. doi:10.1056/NEJMoa2416394
6. Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, Sands SA, Schwab RJ, Dunn JP, Chakladar S, Bunck MC, Bednarik J. Tirzepatide for the treatment of obstructive sleep apnea and obesity. New England Journal of Medicine 2024;391(13):1193–1205. doi:10.1056/NEJMoa2404881 · PMID 38912654
7. Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, Ge J, Weerakkody GJ, Ou Y, Bunck MC, Hurt KC, Murakami M, Borlaug BA. Tirzepatide for heart failure with preserved ejection fraction and obesity. New England Journal of Medicine 2025;392(5):427–437. doi:10.1056/NEJMoa2410027
8. Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, Mao H, Cui X, Karanikas CA, Thieu VT. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet 2021;398(10295):143–155. doi:10.1016/S0140-6736(21)01324-6 · PMID 34186022
9. Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine 2021;385(6):503–515. doi:10.1056/NEJMoa2107519 · PMID 34170647
10. Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, Bray R, Rodríguez Á. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet 2021;398(10300):583–598. doi:10.1016/S0140-6736(21)01443-4 · PMID 34370970
11. Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet 2021;398(10313):1811–1824. doi:10.1016/S0140-6736(21)02188-7 · PMID 34672967
12. Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodríguez Á. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA 2022;327(6):534–545. doi:10.1001/jama.2022.0078 · PMID 35133415
13. Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D’Alessio DA, Haupt A. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism 2018;18:3–14. doi:10.1016/j.molmet.2018.09.009 · PMID 30473097
14. Urva S, Coskun T, Loghin C, Cui X, Beebe E, O’Farrell L, Briere DA, Benson C, Nauck MA, Haupt A. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes, Obesity and Metabolism 2020;22(10):1886–1891. doi:10.1111/dom.14110 · PMID 32519795
15. United States Food and Drug Administration. ZEPBOUND (tirzepatide) injection, for subcutaneous use — Highlights of Prescribing Information. FDA Approved Labeling 2024;Revision 12/2024. identifier not held by the Institute
16. United States Food and Drug Administration. MOUNJARO (tirzepatide) injection, for subcutaneous use — Highlights of Prescribing Information. FDA Approved Labeling 2024;Revision 2024. identifier not held by the Institute
17. European Medicines Agency. Mounjaro (tirzepatide) — Summary of Product Characteristics. EMA European Public Assessment Report 2024;EMEA/H/C/005620. identifier not held by the Institute
18. Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1?. Trends in Endocrinology & Metabolism 2020;31(6):410–421. doi:10.1016/j.tem.2020.02.006 · PMID 32396843

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.